May act as scaffolding protein, and as adapter protein to couple membrane receptors to intracellular signaling pathways (Probable). Acts as a mediator of cell spreading and actin cytoskeleton rearrangement (PubMed:18710924). Core component of the CTLH E3 ubiquitin-protein ligase complex that selectively accepts ubiquitin from UBE2H and mediates ubiquitination and subsequent proteasomal degradation of the transcription factor HBP1 (PubMed:29911972). May be involved in signaling of ITGB2/LFA-1 and other integrins (PubMed:14722085). Enhances HGF-MET signaling by recruiting Sos and activating the Ras pathway (PubMed:12147692). Enhances dihydrotestosterone-induced transactivation activity of AR, as well as dexamethasone-induced transactivation activity of NR3C1, but not affect estrogen-induced transactivation (PubMed:12361945, PubMed:18222118). Stabilizes TP73 isoform Alpha, probably by inhibiting its ubiquitination, and increases its proapoptotic activity (PubMed:15558019). Inhibits the kinase activity of DYRK1A and DYRK1B. Inhibits FMR1 binding to RNA. Part of a complex consisting of RANBP9, MKLN1 and GID8 (PubMed:12559565). Identified in the CTLH complex that contains GID4, RANBP9 and/or RANBP10, MKLN1, MAEA, RMND5A (or alternatively its paralog RMND5B), GID8, ARMC8, WDR26 and YPEL5 (PubMed:17467196, PubMed:29911972). Within this complex, MAEA, RMND5A (or alternatively its paralog RMND5B), GID8, WDR26, and RANBP9 and/or RANBP10 form the catalytic core, while GID4, MKLN1, ARMC8 and YPEL5 have ancillary roles (PubMed:29911972). Interacts with GTP-bound Ran, AR, CDC2L1/p110C, CALB1, S100A7, USP11, MKLN1, SOS1 or SOS2, GID8, and FMR1 (PubMed:11470507, PubMed:9817760, PubMed:12361945, PubMed:12084015, PubMed:12421467, PubMed:12147692, PubMed:12684061, PubMed:14511641, PubMed:14684163, PubMed:15381419, PubMed:18710924). Interacts with the Dyrk kinases HIPK2, DYRK1A, and DYRK1B (PubMed:12220523, PubMed:14500717). Interacts with TP73 isoform Alpha but not with TP53 (PubMed:15558019). Interacts with the HGF receptor MET and the integrins ITGB1 and ITGB2, but not with ITGAL (PubMed:14722085). Part of a complex consisting of RANBP9, RAN, DYRK1B and COPS5 (PubMed:14500717). Directly interacts with RANBP10 (PubMed:18222118). Interacts with YPEL5 (PubMed:20580816). Interacts with DDX4 (PubMed:27622290). Interacts with NGFR (By similarity). Interacts with TEX19 (By similarity). The unphosphorylated form is predominantly cytoplasmic. A phosphorylated form is associated with the plasma membrane. Ubiquitously expressed, with highest levels in testes, placenta, heart, and muscle, and lowest levels in lung. Within the brain, expressed predominantly by neurons in the gray matter of cortex, the granular layer of cerebellum and the Purkinje cells. The SPRY domain mediates the interaction with MET, AR, and CDC2L1. Phosphorylated in response to stress. Can be phosphorylated by the cleaved p110 form of CDC2L1 (p110C). Ubiquitinated. Polyubiquitination targets the protein for rapid degradation via the ubiquitin system. Can be deubiquitinated by USP11. Belongs to the RANBP9/10 family. According to some authors RANBP9 is located in centrosomes and involved in microtubule assembly. Other authors infirmed these results. Contaminating sequence. Potential poly-A sequence. Truncated N-terminus. Truncated N-terminus.